International Forum of Allergy & Rhinology最新文献

Background: Appropriate medical therapy (AMT) is first-line treatment for patients with chronic rhinosinusitis (CRS). We evaluated inflammatory structure, treatment-induced changes, and biomarker-outcome associations in AMT-managed patients.

Methods: Fifty-one CRS patients were evaluated before and after AMT which included a combination of oral antibiotics, oral steroids, or intranasal steroids tailored to CRS phenotype and severity. At each visit, patients completed the SNOT-22, CRS-PRO, Brief Smell Identification Test (BSIT), CT scan (Lund-Mackay Score [LM]), and endoscopy (Modified Lund-Kennedy Score [MLK]). Middle-meatal mucus was analyzed for IL-1b, IL-5, IL-13, IFN-g, and MIP1a using Luminex and ELISA. Principal components analysis (PCA) was performed on baseline cytokine data to identify key biomarker axes. Paired-sample Wilcoxon tests compared cytokine changes, and Spearman's correlation assessed relationships between biomarkers and disease measures.

Results: PCA revealed two major components: PC-1 (inflammation severity) dominated by ECP and MIP1a, and PC-2 (endotype axis) with positive weighting of IL-5 and IL-13 (T2) and negative weighting of IFN-g and IL-1b (T1/3). AMT significantly reduced inflammatory severity and T2 biomarker burden, driven by decreases in IL-5, IL-13, ECP, and MIP1a (all p < 0.01), while T1/3 biomarker remained unchanged. Clinical outcomes, including MLK, SNOT-22, CRS-PRO, and BSIT, improved and showed stronger correlations with T2 than T1/3 biomarkers.

Conclusion: AMT for CRS is associated with reduction in index biomarkers across inflammatory severity and T2 endotype with minimal effects on T1/3 inflammation. T2-driven inflammation appears to be the most AMT-responsive axis found in this study, aligning with measurable improvements in endoscopic, patient reported, and nasal airflow outcomes.

Background: The management of moderate-to-severe allergic rhinitis (AR) is challenging given numerous advanced therapies. A comparative, evidence-based treatment hierarchy to guide the selection of biologics, allergen immunotherapy (AIT), and advanced pharmacotherapies is critically lacking due to a paucity of head-to-head trials. This network meta-analysis established a treatment hierarchy for moderate-to-severe AR by comparing the efficacy and safety of biologics, AIT, and key pharmacotherapies.

Methods: We analyzed 28 randomized controlled trials (13,312 participants), which evaluated the efficacy and safety of biologics (anti-IgE, anti-IL-4Rα therapies), AIT (evaluated within a 6-month time frame to ensure comparability), and key pharmacotherapies (intranasal corticosteroids alone or combined with antihistamines) for moderate-to-severe AR. Efficacy was assessed by changes in the Total Nasal Symptom Score (TNSS), the Total Ocular Symptom Score (TOSS), and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). A treatment hierarchy was established using surface under the cumulative ranking curve (SUCRA) probabilities.

Results: For the TNSS, anti-IL-4Rα therapy was most effective, followed by anti-IgE therapy and AIT, which surpassed all pharmacotherapies. The combination of intranasal corticosteroid and intranasal antihistamine ranked the highest for ocular symptoms. Anti-IL-4Rα therapy was also superior for improving the RQLQ. Overall, all treatments demonstrated a favorable safety profile. Biologics and AIT did not show a significant increase in adverse events risk compared to placebo.

Conclusions: This network meta-analysis establishes the first comprehensive treatment hierarchy for moderate-to-severe AR. Our findings demonstrate that biologics, particularly anti-IL-4Rα therapy, are the most effective interventions for nasal symptom control, ranking superior to AIT and pharmacotherapies, thus providing a robust, data-driven framework to personalize patient care.

Key points: Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.

Background: The role of epithelial dysregulation is poorly understood in fungal sinusitis. We aimed to examine differential gene expression and quantify protease expression in sinonasal tissue from distinct patient cohorts, those with and without invasive fungal sinusitis (IFS). We hypothesized that abnormal epithelial integrity in the sinonasal mucosa of immunosuppressed IFS patients may allow for tissue invasion.

Methods: Bulk RNA sequencing was performed on tissue from eight patients from two cohorts: immunosuppressed patients with and without IFS. Evaluation of protein expression for select proteases and their inhibitors was performed on all sinonasal tissues using multiplex western blotting. To expand upon these findings, protein expression of proteases and their inhibitors was evaluated in sinonasal tissue from eight patients with non-invasive fungal sinusitis (fungal ball).

Results: Bulk RNA sequencing identified 33 genes that were differentially regulated in immunosuppressed IFS tissue compared to those without IFS. Multiplex western blot revealed several proteases, including matrix metalloproteinases (MMPs), with increased expression in the immunosuppressed IFS cohort compared to the cohorts without IFS. Tissue inhibitors of MMPs (TIMPs) were proportionally lower in IFS patient tissue compared to the control cohorts, resulting in several abnormal IFS-related MMP/TIMP ratios. In the non-invasive fungal sinusitis cohort, unique MMP/TIMP ratios were dysregulated.

Conclusions: Several proteases with increased expression in immunosuppressed IFS patients may be responsible for both an appropriate immune response to the pathogen as well as epithelial barrier breakdown and subsequent fungal invasion.

Key points: Environmental and occupational inhalational exposures are linked to chronic rhinosinusitis The Sinonasal Occupational Airborne Pollutant Exposure (SOAPE) survey assesses lifetime exposure to inhalational irritants CRS patients who underwent sinus surgery reported higher inhalational exposures.

Background: Identifying predictive and monitoring biomarkers for allergen immunotherapy response is crucial for enhancing clinical efficacy. This study aims to investigate the systemic and local levels of immunoglobulins and identify potential biomarkers in house dust mite (HDM) allergic rhinitis (AR) patients who are undergoing subcutaneous immunotherapy (SCIT).

Methods: This study enrolled 114 AR patients who completed 1-year SCIT follow-up. High responders and low responders were classified based on >30% improvement in the average total combined score (ATCS). Immunoglobulin levels of HDM and its major components were measured in serum and nasal secretions before and after treatment. Predictive index (Pi) and therapeutic index (Ti) analyses were performed using linear regression to assess the impact of baseline immunoglobulin concentrations and their pre- to post-treatment changes on symptom alleviation. Receiver operating characteristic (ROC) curve analysis with area under the curve (AUC) quantification was performed to evaluate predictive value for clinical responses.

Results: Positive SCIT response correlated with lower baseline age and higher symptom scores, allergen-specific IgE (sIgE) levels, and sIgE/total IgE (tIgE) ratio. Pi analysis revealed that elevated pre-treatment nasal sIgE levels and higher sIgE/tIgE ratios for Der p, Der f, Der p 1, and Der p 2 distinguished high from low responders. Ti analysis showed that post-treatment decreases in these nasal sIgE levels correlated with improved clinical outcomes. Logistic regression showed baseline sIgE/tIgE ratios for Der p and Der f both in serum and nasal secretions, and Der p 1 and Der p 2 in serum positively correlated with clinical improvement. The sIgE/tIgE ratios of Der p (0.833 vs. 0.758) and Der f (0.813 vs. 0.738) in nasal secretions exhibited higher AUC values compared to serum.

Conclusions: Immunologic indicators in nasal secretions are potential biomarkers for the effective prediction and monitoring of early SCIT responses.